Nucleic acid therapeutics: State of the art and future prospects

Blood

Volumn 92, Issue 3, 1998, Pages 712-736

  Gewirtz, Alan M ^a   Sokol, Deborah L ^a   Ratajczak, Mariusz Z ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FUTUROLOGY; GENE EXPRESSION REGULATION; GENE SEQUENCE; GENE THERAPY; HUMAN; MEDICAL RESEARCH; PRIORITY JOURNAL; REVIEW;

EID: 0032147234     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v92.3.712.415a32_712_736     Document Type: Review

References (270)

1. Crystal RG: Transfer of genes to humans: early lessons and obstacles to success. Science 270:404, 1995
2. Verma IM, Somia N: Gene therapy - Promises, problems and prospects [news]. Nature 389:239, 1997
3. Paterson BM, Roberts BE, Kuff EL: Structural gene identification and mapping by DNA-mRNA hybrid-arrested cell-free translation. Proc Natl Acad Sci USA 74:4370, 1977
4. Zamecnik PC, Stephenson ML: Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide. Proc Natl Acad Sci USA 75:280, 1978
5. Simons RW, Kleckner N: Translational control of IS10 transposition. Cell 34:683, 1983
6. Mizuno T, Chou MY, Inouye M: A unique mechanism regulating gene expression: Translational inhibition by a complementary RNA transcript (micRNA). Proc Natl Acad Sci USA 81:1966, 1984
7. Izant JG, Weintraub H: Inhibition of thymidine kinase gene expression by anti-sense RNA: A molecular approach to genetic analysis. Cell 36:1007, 1984
8. Bronson SK, Smithies O: Altering mice by homologous recombination using embryonic stem cells. J Biol Chem 269:27155, 1994
9. Camerini-Otero RD, Hsieh P: Parallel DNA triplexes, homologous recombination, and other homology-dependent DNA interactions. Cell 73:217, 1993
10. Marth JD: Recent advances in gene mutagenesis by site-directed recombination. J Clin Invest 97:1999, 1996
11. Shivdasani RA, Rosenblatt MR Zucker-Franklin D, Jackson CW, Hunt P, Saris CJ, Orkin SH: Transcription factor NF-E2 is required for platelet formation independent of the actions of thrombopoietin/MGDF in megakaryocyte development. Cell 81:695, 1995
12. Luger SM, Ratajczak J, Ratajczak MZ, Kuczynski WI, DiPaola RS, Ngo W, Clevenger CV, Gewirtz AM: A functional analysis of protooncogene Vav's role in adult human hematopoiesis. Blood 87:1326, 1996
13. Gunther EJ, Havre PA, Gasparro FP, Glazer PM: Triplex-mediated, in vitro targeting of psoralen photoadducts within the genome of a transgenic mouse. Photochem Photobiol 63:207, 1996
14. Maher L Jr: Prospects for the therapeutic use of antigene oligonucleotides. Cancer Invest 14:66, 1996
15. Raha M, Wang G, Seidman MM, Glazer PM: Mutagenesis by third-strand-directed psoralen adducts in repair-deficient human cells: high frequency and altered spectrum in a xeroderma pigmentosum variant. Proc Natl Acad Sci USA 93:2941, 1996
16. Afonina I, Kutyavin I, Lukhtanov E, Meyer RB, Gamper H: Sequence-specific arrest of primer extension on single-stranded DNA by an oligonucleotide-minor groove binder conjugate. Proc Natl Acad Sci USA 93:3199, 1996
17. Xodo LE, Alunni-Fabbroni M, Manzini G: Effect of 5-methylcytosine on the structure and stability of DNA. Formation of triple-stranded concatenamers by overlapping oligonucleotides. J Biomol Struct Dyn 11:703, 1994
18. Faucon B, Mergny JL, Helene C: Effect of third strand composition on the triple helix formation: purine versus pyrimidine oligodeoxynucleotides. Nucleic Acids Res 24:3181, 1996
19. Faruqi AF, Krawczyk SH, Matteucci MD, Glazer PM: Potassium-resistant triple helix formation and improved intracellular gene targeting by oligodeoxyribonucleotides containing 7-deazaxanthine. Nucleic Acids Res 25:633, 1997
20. Svinarchuk F, Bertrand JR, Malvy C: A short purine oligonucleotide forms a highly stable triple helix with the promoter of the murine c-pim-1 proto-oncogene. Nucleic Acids Res 22:3742, 1994
21. Maine IP, Kodadek T: Efficient unwinding of triplex DNA by a DNA helicase. Biochem Biophys Res Commun 204:1119, 1994
22. de Bizemont T, Duval-Valentin G, Sun JS, Bisagni E, Garestier T, Helene C: Alternate strand recognition of double-helical DNA by (T,G)-containing oligonucleotides in the presence of a triple helix-specific ligand. Nucleic Acids Res 24:1136, 1996
23. Washbrook E, Fox KR: Alternate-strand DNA triple-helix formation using short acridine-linked oligonucleotides. Biochem J 301:569, 1994
24. Lacoste J, Francois JC, Helene C: Triple helix formation with purine-rich phosphorothioate-containing oligonucleotides covalently linked to an acridine derivative. Nucleic Acids Res 25:1991, 1997
25. Kane SA, Hecht SM, Sun JS, Garestier T, Helene C: Specific cleavage of a DNA triple helix by FeII.bleomycin. Biochemistry 34:16715, 1995
26. Gasparro FP, Havre PA, Olack GA, Gunther EJ, Glazer PM: Site-specific targeting of psoralen photoadducts with a triple helix-forming oligonucleotide: characterization of psoralen monoadduct and crosslink formation. Nucleic Acids Res 22:2845, 1994
27. Grant KB, Dervan PB: Sequence-specific alkylation and cleavage of DNA mediated by purine motif triple helix formation. Biochemistry 35:12313, 1996
28. Wang G, Seidman MM, Glazer PM: Mutagenesis in mammalian cells induced by triple helix formation and transcription-coupled repair. Science 271:802, 1996
29. Kochetkova M, Shannon MF: DNA triplex formation selectively inhibits granulocyte-macrophage colony-stimulating factor gene expression in human T cells. J Biol Chem 271:14438, 1996.
30. Kochetkova M, Iversen PO, Lopez AF, Shannon MF: Deoxyribonucleic acid triplex formation inhibits granulocyte macrophage colony-stimulating factor gene expression and suppresses growth in juvenile myelomonocytic leukemic cells. J Clin Invest 99:3000, 1997
31. Kmiec EB: Genomic targeting and genetic conversion in cancer therapy. Semin Oncol 23:188, 1996
32. Wang G, Levy DD, Seidman MM, Glazer PM: Targeted mutagenesis in mammalian cells mediated by intracellular triple helix formation. Mol Cell Biol 15:1759, 1995
33. Kren BT, Bandyopadhyay P, Steer CJ: In vivo site-directed mutagenesis of the factor IX gene by chimeric RNA/DNA oligonucleotides [see comments]. Nat Med 4:285, 1998
34. Morishita R, Gibbons GH, Horiuchi M, Ellison KE, Nakama M, Zhang L, Kaneda Y, Ogihara T, Dzau VJ: A gene therapy strategy using a transcription factor decoy of the E2F binding site inhibits smooth muscle proliferation in vivo. Proc Natl Acad Sci USA 92:5855, 1995
35. Sharma HW, Perez JR, Higgins-Sochaski K, Hsiao R, Narayanan R: Transcription factor decoy approach to decipher the role of NF-kappa B in oncogenesis. Anticancer Res 16:61, 1996
36. Nellen W, Lichtenstein C: What makes an mRNA anti-senseitive? Trends Biochem Sci 18:419, 1993
37. Shakin SH, Liebhaber SA: Destabilization of messenger RNA/ complementary DNA duplexes by the elongating 80 S ribosome. J Biol Chem 261:16018, 1986
38. Hogrefe HH, Hogrefe RI, Walder RY, Walder JA: Kinetic analysis of Escherichia coli RNase H using DNA-RNA-DNA/DNA substrates. J Biol Chem 265:5561, 1990
39. Eder PS, DeVine RJ, Dagle JM, Walder JA: Substrate specificity and kinetics of degradation of antisense oligonucleotides by a 3′ exonuclease in plasma. Antisense Res Dev 1:141, 1991
40. Agrawal S, Mayrand SH, Zamecnik PC, Pederson T: Site-specific excision from RNA by RNase H and mixed-phosphate-backbone oligodeoxynucleotides. Proc Natl Acad Sci USA 87:1401, 1990
41. Woolf T, Melton D, Jennings C: Specificity of antisense oligonucleotides in vivo. Proc Natl Acad Sci USA 89:7305, 1992
42. Dagle JM, Weeks DL, Walder JA: Pathways of degradation and mechanism of action of antisense oligonucleotides in Xenopus laevis embryos. Antisense Res Dev 1:11, 1991
43. Rosolen A, Kyle E, Chavany C, Bergan R, Kalman ET, Crouch R, Neckers L: Effect of over-expression of bacterial ribonuclease H on the utility of antisense MYC oligodeoxynucleotides in the monocytic leukemia cell line U937. Biochimie 75:797, 1993
44. Moulds C, Lewis JG, Froehler BC, Grant D, Huang T, Milligan JF, Matteucci MD, Wagner RW: Site and mechanism of antisense inhibition by C-5 propyne oligonucleotides. Biochemistry 34:5044, 1995
45. Giles RV, Ruddell CJ, Spiller DG, Green JA, Tidd DM: Single base discrimination for ribonuclease H-dependent antisense effects within intact human leukaemia cells. Nucleic Acids Res 23:954, 1995
46. Giles RV, Spiller DG, Green JA, Clark RE, Tidd DM: Optimization of antisense oligodeoxynucleotide structure for targeting bcr-abl mRNA. Blood 86:744, 1995
47. Kim U, Nishikura K: Double-stranded RNA adenosine deaminase as a potential mammalian RNA editing factor. Semin Cell Biol 4:285, 1993
48. Kim U, Wang Y, Sanford T, Zeng Y, Nishikura K: Molecular cloning of cDNA for double-stranded RNA adenosine deaminase, a candidate enzyme for nuclear RNA editing. Proc Natl Acad Sci USA 91:11457, 1994
49. Kim U, Garner TL, Sanford T, Speicher D, Murray JM, Nishikura K: Purification and characterization of double-stranded RNA adenosine deaminase from bovine nuclear extracts. J Biol Chem 269:13480, 1994
50. Cech TR: The efficiency and versatility of catalytic RNA: implications for an RNA world. Gene 135:33, 1993
51. Cech TR: Catalytic RNA: structure and mechanism. Biochem Soc Trans 21:229, 1993
52. Pyle AM: Ribozymes: A distinct class of metalloenzymes [see comments]. Science 261:709, 1993
53. James HA, Gibson I: The therapeutic potential of ribozymes. Blood 91:371, 1998
54. Ruffner D, Dahm S, Uhlenbeck O: Studies on the hammerhead RNA self-cleaving domain. Gene 82:31, 1989
55. Xing Z, Whitton JL: Ribozymes which cleave arenavirus RNAs: Identification of susceptible target sites and inhibition by target site secondary structure. J Virol 66:1361, 1992
56. Breaker RR, Joyce GF: Inventing and improving ribozyme function: rational design versus iterative selection methods. Trends Biotechnol 12:268, 1994
57. James HA, Turner PC: Ribozymes. Methods Mol Biol 74:1, 1997
58. Gibson SA, Shillitoe EJ: Ribozymes. Their functions and strategies for their use. Mol Biotechnol 7:125, 1997
59. Jaeger L: The new world of ribozymes. Curr Opin Struct Biol 7:324, 1997
60. Homann M, Tzortzakaki S, Rittner K, Sczakiel G, Tabler M: Incorporation of the catalytic domain of a hammerhead ribozyme into antisense RNA enhances its inhibitory effect on the replication of human immunodeficiency virus type 1. Nucleic Acids Res 21:2809, 1993
61. Castanotto D, Rossi JJ, Sarver N: Antisense catalytic RNAs as therapeutic agents. Adv Pharmacol 25:289, 1994
62. Hormes R, Homann M, Oelze I, Marschall P, Tabler M, Eckstein F, Sczakiel G: The subcellular localization and length of hammerhead ribozymes determine efficacy in human cells. Nucleic Acids Res 25:769, 1997
63. Jarvis TC, Wincott FE, Alby LJ, McSwiggen JA, Beigelman L, Gustofson J, DiRenzo A, Levy K, Arthur M, Matulic-Adamic J, Karpeisky A, Gonzalez C, Woolf TM, Usman N, Stinchcomb DT: Optimizing the cell efficacy of synthetic ribozymes. Site selection and chemical modifications of ribozymes targeting the proto-oncogene c-myb. J Biol Chem 271:29107, 1996
64. Sigurdsson ST, Eckstein F: Structure-function relationships of hammerhead ribozymes: From understanding to applications. Trends Biotechnol 13:286, 1995
65. Rittner K, Burmester C, Sczakiel G: In vitro selection of fast-hybridizing and effective antisense RNAs directed against the human immunodeficiency virus type 1. Nucleic Acids Res 21:1381, 1993
66. McConnell TS, Herschlag D, Cech TR: Effects of divalent metal ions on individual steps of the Tetrahymena ribozyme reaction. Biochemistry 36:8293, 1997
67. Nedbal W, Sczakiel G: Hammerhead ribozyme activity in the presence of low molecular weight cellular extract. Antisense Nucleic Acid Drug Dev 7:585, 1997
68. Herschlag D, Cech T: Catalysis of RNA cleavage by the tetrahymena thermophila ribozyme. 1. Kinetic description of the reaction of an RNA substrate complementary to the active site. Biochemistry 29:10159, 1990
69. Sullenger BA, Cech TR: Tethering ribozymes to a retroviral packaging signal for destruction of viral RNA. Science 262:1566, 1993
70. Bertrand E, Castanotto D, Zhou C, Carbonnelle C, Lee NS, Good P, Chatterjee S, Grange T, Pictet R, Kohn D, Engelke D, Rossi JJ: The expression cassette determines the functional activity of ribozymes in mammalian cells by controlling their intracellular localization. RNA 3:75, 1997
71. Good PD, Krikos AJ, Li SX, Bertrand E, Lee NS, Giver L, Ellington A, Zaia JA, Rossi JJ, Engelke DR: Expression of small, therapeutic RNAs in human cell nuclei. Gene Ther 4:45, 1997
72. Jones JT, Sullenger BA: Evaluating and enhancing ribozyme reaction efficiency in mammalian cells. Nat Biotechnol 15:902, 1997
73. Sigurdsson ST, Tuschl T, Eckstein F: Probing RNA tertiary structure: interhelical crosslinking of the hammerhead ribozyme, RNA 1:575, 1995
74. Lee NS, Bertrand E, Rossi JJ: Enhancement of ribozyme function by RNA binding proteins. Methods Mol Biol 74:275, 1997
75. Lee TC, Sullenger BA, Gallardo HF, Ungers GE, Gilboa E: Overexpression of RRE-derived sequences inhibits HIV-1 replication in CEM cells. New Biol 4:66, 1992
76. Junker U, Rittner K, Homann M, Bevec D, Bohnlein E, Sczakiel G: Reduction in replication of the human immunodeficiency virus type 1 in human T cell lines by polymerase III-driven transcription of chimeric tRNA-antisense RNA genes. Antisense Res Dev4:165, 1994
77. Sullenger BA, Gallardo HF, Ungers GE, Gilboa E: Analysis of trans-acting response decoy RNA-mediated inhibition of human immunodeficiency virus type 1 transactivation. J Virol 65:6811, 1991
78. Khan IM, Coulson JM: A novel method to stabilise antisense oligonucleotides against exonuclease degradation [published erratum appears in Nucleic Acids Res 21:4433,1993]. Nucleic Acids Res 21:2957, 1993
79. Wagner RW, Matteucci MD, Grant D, Huang T, Froehler BC: Potent and selective inhibition of gene expression by an antisense heptanucleotide. Nature Biotechnol 14:840, 1996
80. Dewanjee MK, Ghafouripour AK, Kapadvanjwala M, Dewanjee S, Serafini AN, Lopez DM, Sfakianakis GN: Noninvasive imaging of c-myc oncogene messenger RNA with indium-111 -antisense probes in a mammary tumor-bearing mouse model [see comments]. J Nucl Med 35:1054, 1994
81. Gewirtz AM, Stein CA, Glazer PM: Facilitating oligonucleotide delivery: helping antisense deliver on its promise. Proc Natl Acad Sci USA 93:3161, 1996
82. Oligonucleotides as Therapeutic Agents. Symposium on Oligonucleotides as Therapeutic Agents. London, UK, January 1997
83. Crooke ST: Advances in understanding the pharmacological properties of antisense oligonucleotides. Adv Pharmacol 40:1, 1997
84. Ratajczak MZ, Hijiya N, Catani L, DeRiel K, Luger SM, McGlave P, Gewirtz AM: Acute- and chronic-phase chronic myelogenous leukemia colony-forming units are highly sensitive to the growth inhibitory effects of c-myb antisense oligodeoxynucleotides. Blood 79:1956, 1992
85. Ratajczak MZ, Luger SM, DeRiel K, Abrahm J, Calabretta B, Gewirtz AM: Role of the KIT protooncogene in normal and malignant human hematopoiesis. Proc Natl Acad Sci USA 89:1710, 1992
86. Small D, Levenstein M, Kim E, Carow C, Amin S, Rockwell P, Witte L, Burrow C, Ratajczak MZ, Gewirtz AM, Civin C: STK-1, the human homolog of Flk-2/Flt-3, is selectively expressed in CD34+ human bone marrow cells and is involved in the proliferation of early progenitor/stem cells. Proc Natl Acad Sci USA 91:459, 1994
87. Ratajczak MZ, Kuczynski WI, Onodera K, Moore J, Ratajczak J, Kregenow DA, DeRiel K, Gewirtz AM: A reappraisal of the role of insulin-like growth factor I in the regulation of human hematopoiesis. J Clin Invest 94:320, 1994
88. Ratajczak MZ, Kuczynski WI, Sokol DL, Moore JS, Pletcher CH Jr, Gewirtz AM: Expression and physiologic significance of Kit ligand and stem cell tyrosine kinase-1 receptor ligand in normal human CD34+, c-Kit+ marrow cells. Blood 86:2161, 1995
89. Zon G: Antisense phosphorothioate oligodeoxynucleotides: introductory concepts and possible molecular mechanisms of toxicity. Toxicol Lett 82-83:419, 1995
90. Crooke ST: Antisense technology. Curr Opin Biotechnol 2:282, 1991
91. Miller PS: Oligonucleoside methylphosphonates as antisense reagents. Biotechnology (NY) 9:358, 1991
92. Giles RV, Spiller DG, Tidd DM: Chimeric oligodeoxynucleotide analogues: enhanced cell uptake of structures which direct ribonuclease H with high specificity. Anticancer Drug Des 8:33, 1993
93. Gewirtz AM, Luger S, Sokol D, Gowdin B, Stadtmauer E, Reccio A, Ratajczak MZ: Oligodeoxynucleotide therapeutics for human myelogenous leukemia: Interim results. Blood 88:270a, 1996 (abstr, suppl1)
94. de Fabritiis P, Calabretta B: Antisense oligodeoxynucleotides for the treatment of chronic myelogenous leukemia: Are they still a promise? [editorial]. Haematologica 80:295, 1995
95. Webb A, Cunningham D, Cotter F, Clarke PA, di Stefano F, Ross P, Corbo M, Dziewanowska Z: BCL-2 antisense therapy in patients with non-Hodgkin lymphoma. Lancet 349:1137, 1997
96. DeLong RK, Molting A, Fisher M, Chen Q, Wickstrom E, Kligshteyn M, Demirdji S, Caruthers M, Juliano RL: Comparative pharmacokinetics, tissue distribution, and tumor accumulation of phosphorothioate, phosphorodithioate, and methylphosphonate oligonucleotides in nude mice. Antisense Nucleic Acid Drug Dev 7:71, 1997
97. Stein CA, Krieg AM: Problems in interpretation of data derived from in vitro and in vivo use of antisense oligodeoxynucleotides [editorial]. Antisense Res Dev 4:67, 1994
98. Stein CA: Does antisense exist? Nat Med 1:1119, 1995
99. Wagner RW, Flanagan WM: Antisense technology and prospects for therapy of viral infections and cancer. Mol Med Today 3:31, 1997
100. Guvakova MA, Yakubov LA, Vlodavsky I, Tonkinson JL, Stein CA: Phosphorothioate oligodeoxynucleotides bind to basic fibroblast growth factor, inhibit its binding to cell surface receptors, and remove it from low affinity binding sites on extracellular matrix. J Biol Chem 270:2620, 1995
101. Iversen PL, Copple BL, Tewary HK: Pharmacology and toxicology of phosphorothioate oligonucleotides in the mouse, rat, monkey and man. Toxicol Lett 82-83:425, 1995
102. Shaw DR, Rustagi PK, Kandimalla ER, Manning AN, Jiang Z, Agrawal S: Effects of synthetic oligonucleotides on human complement and coagulation. Biochem Pharmacol 53:1123, 1997
103. Gao WY, Han FS, Storm C, Egan W, Cheng YC: Phosphorothioate oligonucleotides are inhibitors of human DNA polymerases and RNase H: Implications for antisense technology. Mol Pharmacol 41:223, 1992
104. Skutella T, Montkowski A, Stohr T, Probst JC, Landgraf R, Holsboer F, Jirikowski GF: Corticotropin-releasing hormone (CRH) antisense oligodeoxynucleotide treatment attenuates social defeat-induced anxiety in rats. Cell Mol Neurobiol 14:579, 1994
105. Thierry AR, Dritschilo A: Intracellular availability of unmodified, phosphorothioated and liposomally encapsulated oligodeoxynucleotides for antisense activity. Nucleic Acids Res 20:5691, 1992
106. Agrawal S, Jiang Z, Zhao Q, Shaw D, Cai Q, Roskey A, Channavajjala L, Saxinger C, Zhang R: Mixed-backbone oligonucleotides as second generation antisense oligonucleotides: In vitro and in vivo studies. Proc Natl Acad Sci USA 94:2620, 1997
107. Chen JK, Schultz RG, Lloyd DH, Gryaznov SM: Synthesis of oligodeoxyribonucleotide N3′ → P5′ phosphoramidates. Nucleic Acids Res 23:2661, 1995
108. DeDionisio L, Gryaznov SM: Analysis of a ribonuclease H digestion of N3′ → P5′ phosphoramidate-RNA duplexes by capillary gel electrophoresis. J Chromatogr B Biomed Appl 669:125, 1995
109. Gryaznov S, Skorski T, Cucco C, Nieborowska-Skorska M, Chiu CY, Lloyd D, Chen JK, Koziolkiewicz M, Calabretta B: Oligonucleotide N3′ → P5′ phosphoramidates as antisense agents. Nucleic Acids Res 24:1508, 1996
110. Morvan F, Porumb H, Degols G, Lefebvre I, Pompon A, Sproat BS, Rayner B, Malvy C, Lebleu B, Imbach JL: Comparative evaluation of seven oligonucleotide analogues as potential antisense agents. J Med Chem 36:280, 1993
111. Lavignon M, Tounekti N, Rayner B, Imbach JL, Keith G, Paoletti J, Malvy C: Inhibition of murine leukemia viruses by nuclease-resistant alpha-oligonucleotides. Antisense Res Dev 2:315, 1992
112. Gottikh M, Baud-Demattei MV, Lescot E, Giorgi-Renault S, Shabarova Z, Dautry F, Malvy C, Bertrand JR: In vitro inhibition of the pim-1 protooncogene by chimeric oligodeoxyribonucleotides composed of alpha- and beta-anomeric fragments. Gene 149:5, 1994
113. Monia BP, Lesnik EA, Gonzalez C, Lima WF, McGee D, Guinosso CJ, Kawasaki AM, Cook PD, Freier SM: Evaluation of 2′-modified oligonucleotides containing 2′-deoxy gaps as antisense inhibitors of gene expression. J Biol Chem 268:14514, 1993
114. Agrawal S, Zhang X, Lu Z, Zhao H, Tamburin JM, Yan J, Cai H, Diasio RB, Habus I, Jiang Z, Iyer RP, Yu D, Zhang R: Absorption, tissue distribution and in vivo stability in rats of a hybrid antisense oligonucleotide following oral administration. Biochem Pharmacol 50:571, 1995
115. Gutierrez AJ, Matteucci MD, Grant D, Matsumura S, Wagner RW, Froehler BC: Antisense gene inhibition by C-5-substituted deoxyuridine-containing oligodeoxynucleotides. Biochemistry 36:743, 1997
116. Lewis JG, Lin KY, Kothavale A, Flanagan WM, Matteucci MD, DePrince RB, Mook RA Jr, Hendren RW, Wagner RW: A serum-resistant cytofectin for cellular delivery of antisense oligodeoxynucleotides and plasmid DNA. Proc Natl Acad Sci USA 93:3176, 1996
117. Nielsen PE, Egholm M, Berg RH, Buchardt O: Peptide nucleic acids (PNAs): Potential antisense and anti-gene agents. Anticancer Drug Des 8:53, 1993
118. Nielsen PE: DNA analogues with nonphosphosphodiester backbones. Annu Rev Biophys Biomol Struct 24:167, 1995
119. Wittung P, Kajanus J, Edwards K, Haaima G, Nielsen PE, Norden B, Malmstrom BG: Phospholipid membrane permeability of peptide nucleic acid [corrected and republished with original paging, article originally printed in FEBS Lett 365:27,1995]. FEBS Lett 375:27, 1995
120. Kool ET: Circular oligonucleotides: new concepts in oligonucleotide design. Annu Rev Biophys Biomol Struct 25:1, 1996
121. Beaudry D, Perreault JP: An efficient strategy for the synthesis of circular RNA molecules. Nucleic Acids Res 23:3064, 1995
122. Rubin E, Rumney St, Wang S, Kool ET: Convergent DNA synthesis: A non-enzymatic dimerization approach to circular oligodeoxynucleotides. Nucleic Acids Res 23:3547, 1995
123. Perreault T, Baribeau J: Characterization of endothelin receptors in newborn piglet lung. Am J Physiol 268:L607, 1995
124. Wang S, Kool ET: Circular RNA oligonucleotides. Synthesis, nucleic acid binding properties, and a comparison with circular DNAs. Nucleic Acids Res 22:2326, 1994
125. Benimetskaya L, Berton M, Kolbanovsky A, Benimetsky S, Stein CA: Formation of a G-tetrad and higher order structures correlates with biological activity of the RelA (NF-kappaB p65) 'antisense' oligodeoxynucleotide. Nucleic Acids Res 25:2648, 1997
126. Castanotto D, Bertrand E, Rossi J: Exogenous cellular delivery of ribozymes and ribozyme encoding DNAs. Methods Mol Biol 74:429, 1997
127. Khan IM, Coulson JM: A novel method to stabilise antisense oligonucleotides against exonuclease degradation. Nucleic Acids Res 21:4433, 1993
128. Fakler B, Herlitze S, Amthor B, Zenner HP, Ruppersberg JP: Short antisense oligonucleotide-mediated inhibition is strongly dependent on oligo length and concentration but almost independent of location of the target sequence. J Biol Chem 269:16187, 1994
129. Lima WF, Monia BP, Ecker DJ, Freier SM: Implication of RNA structure on antisense oligonucleotide hybridization kinetics. Biochemistry 31:12055, 1992
130. Lima WF, Mohan V, Crooke ST: The influence of antisense oligonucleotide-induced RNA structure on Escherichia coli RNase H1 activity. J Biol Chem 272:18191, 1997
131. Lima WF, Brown-Driver V, Fox M, Hanecak R, Bruice TW: Combinatorial screening and rational optimization for hybridization to folded hepatitis C virus RNA of oligonucleotides with biological antisense activity. J Biol Chem 272:626, 1997
132. Bacon TA, Wickstrom E: Walking along human c-myc mRNA with antisense oligodeoxynucleotides: Maximum efficacy at the 5′ cap region. Oncogene Res 6:13, 1991
133. Stewart AJ, Canitrot Y, Baracchini E, Dean NM, Deeley RG, Cole SP: Reduction of expression of the multidrug resistance protein (MRP) in human tumor cells by antisense phosphorothioate oligonucleotides. Biochem Pharmacol 51:461, 1996
134. Mishra RK, Toulme JJ: In vitro selection of antisense oligonucleotides targeted to a hairpin structure. C R Acad Sci III 317:977, 1994
135. Sczakiel G, Homann M, Rittner K: Computer-aided search for effective antisense RNA target sequences of the human immunodeficiency virus type 1. Antisense Res Dev 3:45, 1993
136. Ho SP, Bao Y, Lesher T, Malhotra R, Ma LY, Fluharty SJ, Sakai RR: Mapping of RNA accessible sites for antisense experiments with oligonucleotide libraries [see comments]. Nat Biotechnol 16:59, 1998
137. Kronenwett R, Haas R, Sczakiel G: Kinetic selectivity of complementary nucleic acids: ber-abl-directed antisense RNA and ribozymes. J Mol Biol 259:632, 1996
138. Stull RA, Taylor LA, Szoka FC Jr: Predicting antisense oligonucleotide inhibitory efficacy: A computational approach using histograms and thermodynamic indices. Nucleic Acids Res 20:3501, 1992
139. Milner N, Mir KU, Southern EM: Selecting effective antisense reagents on combinatorial oligonucleotide arrays [see comments]. Nat Biotechnol 15:537, 1997
140. Sokol DL, Zhang X, Gewirtz AM: Direct in vivo detection of hybridization between antisense oligodeoxynucleotides and target mRNA. Blood 90:418b, 1997 (abstr, suppl 1)
141. Bennett RM: As nature intended? The uptake of DNA and oligonucleotides by eukaryotic cells. Antisense Res Dev 3:235, 1993
142. Yakubov LA, Deeva EA, Zarytova VF, Ivanova EM, Ryte AS, Yurchenko LV, Vlassov VV: Mechanism of oligonucleotide uptake by cells: involvement of specific receptors? Proc Natl Acad Sci USA 86:6454, 1989
143. Loke SL, Stein CA, Zhang XH, Mori K, Nakanishi M, Subasinghe C, Cohen JS, Neckers LM: Characterization of oligonucleotide transport into living cells. Proc Natl Acad Sci USA 86:3474, 1989
144. Stein CA, Neckers LM, Nair BC, Mumbauer S, Hoke G, Pal R: Phosphorothioate oligodeoxycytidine interferes with binding of HIV-1 gp120 to CD4. J Acquir Immune Defic Syndr 4:686, 1991
145. Geselowitz DA, Neckers LM: Analysis of oligonucleotide binding, internalization, and intracellular trafficking utilizing a novel radiolabeled crosslinker. Antisense Res Dev 2:17, 1992
146. Gao WY, Storm C, Egan W, Cheng YC: Cellular pharmacology of phosphorothioate homooligodeoxynucleotides in human cells. Mol Pharmacol 43:45, 1993
147. Beltinger C, Saragovi HU, Smith RM, LeSauteur L, Shah N, DeDionisio L, Christensen L, Raible A, Jarett L, Gewirtz AM: Binding, uptake, and intracellular trafficking of phosphorothioate-modified oligodeoxynucleotides. J Clin Invest 95:1814, 1995
148. Tao LF, Marx KA, Wongwit W, Jiang Z, Agrawal S, Coleman RM: Uptake, intracellular distribution, and stability of oligodeoxynucleotide phosphorothioate by Schistosoma mansoni. Antisense Res Dev 5:123, 1995
149. Gray GD, Basu S, Wickstrom E: Transformed and immortalized cellular uptake of oligodeoxynucleoside phosphorothioates, 3′-alkylamino oligodeoxynucleotides, 2′-O-methyl oligoribonucleotides, oligodeoxynucleoside methylphosphonates, and peptide nucleic acids. Biochem Pharmacol 53:1465, 1997
150. Zhao Q, Matson S, Herrera CJ, Fisher E, Yu H, Krieg AM: Comparison of cellular binding and uptake of antisense phosphodiester, phosphorothioate, and mixed phosphorothioate and methylphosphonate oligonucleotides. Antisense Res Dev 3:53, 1993
151. Li B, Hughes JA, Phillips MI: Uptake and efflux of intact antisense phosphorothioate deoxyoligonucleotide directed against angiotensin receptors in bovine adrenal cells. Neurochem Int 31:393, 1997
152. Clark RE: Poor cellular uptake of antisense oligodeoxynucleotides: An obstacle to their use in chronic myeloid leukaemia. Leuk Lymphoma 19:189, 1995
153. Dean NM, McKay R: Inhibition of protein kinase C-alpha expression in mice after systemic administration of phosphorothioate antisense oligodeoxynucleotides. Proc Natl Acad Sci USA 91:11762, 1994
154. Kola I, Sumarsono SH: Microinjection of in vitro transcribed RNA and antisense oligonucleotides in mouse oocytes and early embryos to study the gain- and loss-of-function of genes. Methods Mol Biol 37:135, 1995
155. Leonetti JP, Mechti N, Degols G, Gagnor C, Lebleu B: Intracellular distribution of microinjected antisense oligonucleotides. Proc Natl Acad Sci USA 88:2702, 1991
156. Bergan R, Hakim F, Schwartz GN, Kyle E, Cepada R, Szabo JM, Fowler D, Gress R, Neckers L: Electroporation of synthetic oligodeoxynucleotides: a novel technique for ex vivo bone marrow purging. Blood 88:731, 1996
157. Flanagan WM, Wagner RW: Potent and selective gene inhibition using antisense oligodeoxynucleotides. Mol Cell Biochem 172:213, 1997
158. Wu-Pong S, Weiss TL, Hunt CA: Calcium dependent cellular uptake of a c-myc antisense oligonucleotide. Cell Mol Biol 40:843, 1994
159. Froystein NA, Sletten E: The binding of manganese(II) and zinc(II) to the synthetic oligonucleotide d(C-G-C-G-A-A-T-T-C-G-C-G)2.A 1H NMR study. Acta Chem Scand 45:219, 1991
160. Juliano RL, Akhtar S: Liposomes as a drug delivery system for antisense oligonucleotides. Antisense Res Dev 2:165, 1992
161. Behr JP: Gene transfer with synthetic cationic amphiphiles: prospects for gene therapy. Bioconjug Chem 5:382, 1994
162. Boussif O, Lezoualc'h F, Zanta MA, Mergny MD, Scherman D, Demeneix B, Behr JP: A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: Polyethylenimine. Proc Natl Acad Sci USA 92:7297, 1995
163. Wyman TB, Nicol F, Zelphati O, Scaria PV, Plank C, Szoka FC Jr: Design, synthesis, and characterization of a cationic peptide that binds to nucleic acids and permeabilizes bilayers. Biochemistry 36:3008, 1997
164. Radler JO, Koltover I, Salditt T, Safinya CR: Structure of DNA-cationic liposome complexes: DNA intercalation in multilamellar membranes in distinct interhelical packing regimes [see comments]. Science 275:810, 1997
165. Zelphati O, Szoka FC Jr: Mechanism of oligonucleotide release from cationic liposomes. Proc Natl Acad Sci USA 93:11493, 1996
166. Xu Y, Szoka FC Jr: Mechanism of DNA release from cationic liposome/DNA complexes used in cell transfection. Biochemistry 35:5616, 1996
167. Aoki M, Morishita R, Higaki J, Moriguchi A, Kida I, Hayashi S, Matsushita H, Kaneda Y, Ogihara T: In vivo transfer efficiency of antisense oligonucleotides into the myocardium using HVJ-liposome method. Biochem Biophys Res Commun 231:540, 1997
168. Desjardins J, Mata J, Brown T, Graham D, Zon G, Iversen P: Cholesteryl-conjugated phosphorothioate oligodeoxynucleotides modulate CYP2B1 expression in vivo. J Drug Target 2:477, 1995
169. Krieg AM, Tonkinson J, Matson S, Zhao Q, Saxon M, Zhang LM, Bhanja U, Yakubov L, Stein CA: Modification of antisense phosphodiester oligodeoxynucleotides by a 5′ cholesteryl moiety increases cellular association and improves efficacy. Proc Natl Acad Sci USA 90:1048, 1993
170. Ma DD, Wei AQ: Enhanced delivery of synthetic oligonucleotides to human leukaemic cells by liposomes and immunoliposomes. Leuk Res 20:925, 1996
171. Kronenwett R, Steidl U, Kirsch M, Sczakiel G, Haas R: Oligodeoxyribonucleotide uptake in primary human hematopoietic cells is enhanced by cationic lipids and depends on the hematopoietic cell subset. Blood 91:852, 1998
172. Liang WW, Shi X, Deshpande D, Malanga CJ, Rojanasakul Y: Oligonucleotide targeting to alveolar macrophages by mannose receptor-mediated endocytosis. Biochim Biophys Acta 1279:227, 1996
173. Kuijpers WH, Bos ES, Kaspersen FM, Veeneman GH, van Boeckel CA: Specific recognition of antibody-oligonucleotide conjugates by radiolabeled antisense nucleotides: A novel approach for two-step radioimmunotherapy of cancer. Bioconjug Chem 4:94, 1993
174. Lu XM, Fischman AJ, Jyawook SL, Hendricks K, Tompkins RG, Yarmush ML: Antisense DNA delivery in vivo: Liver targeting by receptor-mediated uptake. J Nucl Med 35:269, 1994
175. Bonfils E, Depierreux C, Midoux P, Thuong NT, Monsigny M, Roche AC: Drug targeting: Synthesis and endocytosis of oligonucleotide-neoglycoprotein conjugates. Nucleic Acids Res 20:4621, 1992
176. Cerruzi M, Draper K, Schwartz J: Natural and phosphorothioate-modified oligodeoxyribonucleotides exhibit a non-random cellular distribution. Nucleosides Nucleotides 9:679, 1990
177. Clarenc JP, Lebleu B, Leonetti JP: Characterization of the nuclear binding sites of oligodeoxyribonucleotides and their analogs. J Biol Chem 268:5600, 1993
178. Bongartz JP, Aubertin AM, Milhaud PG, Lebleu B: Improved biological activity of antisense oligonucleotides conjugated to a fusogenic peptide. Nucleic Acids Res 22:4681, 1994
179. Cotten M, Wagner E, Zatloukal K, Phillips S, Curiel DT, Birnstiel ML: High-efficiency receptor-mediated delivery of small and large (48 kilobase gene constructs using the endosome-disruption activity of defective or chemically inactivated adenovirus particles. Proc Natl Acad Sci USA 89:6094, 1992
180. Curiel DT, Agarwal S, Romer MU, Wagner E, Cotten M, Birnstiel ML, Boucher RC: Gene transfer to respiratory epithelial cells via the receptor-mediated endocytosis pathway. Am J Respir Cell Mol Biol 6:247, 1992
181. Sullenger BA: Colocalizing ribozymes with substrate RNAs to increase their efficacy as gene inhibitors. Appl Biochem Biotechnol 54:57, 1995
182. Temsamani J, Roskey A, Chaix C, Agrawal S: In vivo metabolic profile of a phosphorothioate Oligodeoxyribonucleotide. Antisense Nucleic Acid Drug Dev 7:159, 1997
183. Agrawal S, Temsamani J, Tang JY: Pharmacokinetics, biodistribution, and stability of oligodeoxynucleotide phosphorothioates in mice. Proc Natl Acad Sci USA 88:7595, 1991
184. Butler M, Stecker K, Bennett CF: Cellular distribution of phosphorothioate oligodeoxynucleotides in normal rodent tissues. Lab Invest 77:379, 1997
185. Iversen PL, Mata J, Tracewell WG, Zon G: Pharmacokinetics of an antisense phosphorothioate oligodeoxynucleotide against rev from human immunodeficiency virus type 1 in the adult male rat following single injections and continuous infusion. Antisense Res Dev 4:43, 1994
186. Sands H, Gorey-Feret LJ, Cocuzza AJ, Hobbs FW, Chidester D, Trainor GL: Biodistribution and metabolism of internally 3H-labeled oligonucleotides. I. Comparison of a phosphodiester and a phosphorothioate. Mol Pharmacol 45:932, 1994
187. Srinivasan SK, Iversen P: Review of in vivo pharmacokinetics and toxicology of phosphorothioate oligonucleotides. J Clin Lab Anal 9:129, 1995
188. Bayever E, Iversen PL, Bishop MR, Sharp JG, Tewary HK, Arneson MA, Pirruccello SJ, Ruddon RW, Kessinger A, Zon G, Armitage JO: Systemic administration of a phosphorothioate oligonucleotide with a sequence complementary to p53 for acute myelogenous leukemia and myelodysplastic syndrome: initial results of a phase I trial. Antisense Res Dev 3:383, 1993
189. Zhang R, Van J, Shahinian H, Amin G, Lu Z, Liu T, Saag MS, Jiang Z, Temsamani J, Martin RR, Schechter PJ, Agrawal S, Diasio RB: Pharmacokinetics of an anti-human immunodeficiency virus antisense oligodeoxynucleotide phosphorothioate (GEM 91) in HIV-infected subjects. Clin Pharmacol Ther 58:44, 1995
190. Stein CA, Cheng YC: Antisense oligonucleotides as therapeutic agents - Is the bullet really magical? Science 261:1004, 1993
191. Galbraith WM, Hobson WC, Giclas PC, Schechter PJ, Agrawal S: Complement activation and hemodynamic changes following intravenous administration of phosphorothioate oligonucleotides in the monkey. Antisense Res Dev 4:201, 1994
192. Leeds JM, Henry SP, Truong L, Zutshi A, Levin AA, Kornbrust D: Pharmacokinetics of a potential human cytomegalovirus therapeutic, a phosphorothioate oligonucleotide, after intravitreal injection in the rabbit. Drug Metab Dispos 25:921, 1997
193. Robertson D: Crohn's trial shows the pros of antisense [news]. Nat Biotechnol 15:209, 1997
194. Calabretta B, Sims RB, Valtieri M, Caracciolo D, Szczylik C, Venturelli D, Ratajczak M, Beran M, Gewirtz AM: Normal and leukemic hematopoietic cells manifest differential sensitivity to inhibitory effects of c-myb antisense oligodeoxynucleotides: an in vitro study relevant to bone marrow purging. Proc Natl Acad Sci USA 88:2351, 1991
195. Ratajczak MZ, Kant JA, Luger SM, Hijiya N, Zhang J, Zon G, Gewirtz AM: In vivo treatment of human leukemia in a scid mouse model with c-myb antisense oligodeoxynucleotides. Proc Natl Acad Sci USA 89:11823, 1992
196. Melo JV: The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype [editorial; comment] [see comments]. Blood 88:2375, 1996
197. Szczylik C, Skorski T, Nicolaides NC, Manzella L, Malaguarnera L, Venturelli D, Gewirtz AM, Calabretta B: Selective inhibition of leukemia cell proliferation by BCR-ABL antisense oligodeoxynucleotides. Science 253:562, 1991
198. Skorski T, Szczylik C, Malaguarnera L, Calabretta B: Gene-targeted specific inhibition of chronic myeloid leukemia cell growth by BCR-ABL antisense oligodeoxynucleotides. Folia Histochem Cytobiol 29:85, 1991
199. Wu AG, Joshi SS, Chan WC, Iversen PL, Jackson JD, Kessinger A, Pirruccello SJ, Sanger WG, Sharp JG, Verbik DJ, Whalen VL, Bishop MR: Effects of BCR-ABL antisense oligonucleotides (AS-ODN) on human chronic myeloid leukemic cells: AS-ODN as effective purging agents. Leuk Lymphoma 20:67, 1995
200. de Fabritiis P, Amadori S, Calabretta B, Mandelli F: Elimination of clonogenic Philadelphia-positive cells using BCR-ABL antisense oligodeoxynucleotides. Bone Marrow Transplant 12:261, 1993
201. de Fabritiis P, Skorski T, De Propris MS, Paggi MG, Nieborowska-Skorska M, Lisci A, Buffolino S, Campbell K, Geiser T, Calabretta B: Effect of bcr-abl oligodeoxynucleotides on the clonogenic growth of chronic myelogenous leukaemia cells. Leukemia 11:811, 1997
202. de Fabritis P, Amadori S, Petti MC, Mancini M, Montefusco E, Picardi A, Geiser T, Campbell K, Calabretta B, Mandelli F: In vitro purging with BCR-ABL antisense oligodeoxynucleotides does not prevent haematologic reconstitution after autologous bone marrow transplantation. Leukemia 9:662, 1995
203. Chasty R, Whetton A, Lucas G: A comparison of the effect of bcr/abl breakpoint specific phosphothiorate oligodeoxynucleotides on colony formation by bcr/abl positive and negative, CD34 enriched mononuclear cell populations. Leuk Res 20:391, 1996
204. Kirkland MA, O'Brien SG, McDonald C, Davidson RJ, Cross NC, Goldman JM: BCR-ABL antisense purging in chronic myeloid leukaemia [letter; comment]. Lancet 342:614, 1993
205. Maekawa T, Kimura S, Hirakawa K, Murakami A, Zon G, Abe T: Sequence specificity on the growth suppression and induction of apoptosis of chronic myeloid leukemia cells by BCR-ABL anti-sense oligodeoxynucleoside phosphorothioates. Int J Cancer 62:63, 1995
206. Mahon FX, Belloc F, Vianes I, Barbot C, Boiron JM, Cowen D, Lacombe F, Brizard A, Bilhou-Nabera C, Bernard P, Braustet A, Reiffers J: Specific antisense oligomer anti Bcr-abl junctions in chronic myeloid leukemia: A cell cycle analysis and CFU-GM study. Leuk Lymphoma 19:423, 1995
207. Mahon FX, Ripoche J, Pigeonnier V, Jazwiec B, Pigneux A, Moreau JF, Reiffers J: Inhibition of chronic myelogenous leukemia cells harboring a BCR-ABL B3A2 junction by antisense oligonucleotides targeted at the B2A2 junction. Exp Hematol 23:1606, 1995
208. O'Brien SG, Kirkland MA, Melo JV, Rao MH, Davidson RJ, McDonald C, Goldman JM: Antisense BCR-ABL oligomers cause non-specific inhibition of chronic myeloid leukemia cell lines. Leukemia 8:2156, 1994
209. Smetsers TF, van de Locht LT, Pennings AH, Wessels HM, de Witte TM, Mensink EJ: Phosphorothioate BCR-ABL antisense oligonucleotides induce cell death, but fail to reduce cellular bcr-abl protein levels. Leukemia 9:118, 1995
210. Vaerman JL, Lammineur C, Moureau P, Lewalle P, Deldime F, Blumenfeld M, Maniat P: BCR-ABL antisense oligodeoxyribonucleotides suppress the growth of leukemic and normal hematopoietic cells by a sequence-specific but nonantisense mechanism. Blood 86:3891, 1995
211. Leopold LH, Shore SK, Reddy EP: Multi-unit anti-BCR-ABL ribozyme therapy in chronic myelogenous leukemia. Leuk Lymphoma 22:365, 1996
212. Lange W, Daskalakis M, Finke J, Dolken G: Comparison of different ribozymes for efficient and specific cleavage of BCR/ABL related mRNAs. FEBS Lett 338:175, 1994
213. Pachuk CJ, Yoon K, Moelling K, Coney LR: Selective cleavage of bcr-abl chimeric RNAs by a ribozyme targeted to non-contiguous sequences. Nucleic Acids Res 22:301, 1994
214. Zhao RC, McIvor RS, Griffin JD, Verfaillie CM: Gene therapy for chronic myelogenous leukemia (CML): A retroviral vector that renders hematopoietic progenitors methotrexate-resistant and CML progenitors functionally normal and nontumorigenic in vivo. Blood 90:4687, 1997
215. Skorski T, Nieborowska-Skorska M, Nicolaides NC, Szczylik C, Iversen P, Iozzo RV, Zon G, Calabretta B: Suppression of Philadelphia 1 leukemia cell growth in mice by BCR-ABL antisense oligodeoxynucleotide. Proc Natl Acad Sci USA91:4504, 1994
216. Skorski T, Nieborowska-Skorska M, Barletta C, Malaguarnera L, Szcyzlik C, Chen ST, Lange B, Calabretta B: Highly efficient elimination of Philadelphia leukemic cells by exposure to bcr/abl antisense oligodeoxynucleotides combined with mafosfamide. J Clin Invest 92:194, 1993
217. Skorski T, Nieborowska-Skorska M, Wlodarski P, Perrotti D, Hoser G, Kawiak J, Majewski M, Christensen L, Iozzo RV, Calabretta B: Treatment of Philadelphia leukemia in severe combined immunodeficient mice by combination of cyclophosphamide and bcr/abl antisense oligodeoxynucleotides [see comments]. J Natl Cancer Inst 89:124, 1997
218. Bedi A, Zehnbauer BA, Collector MI, Barber JP, Zicha MS, Sharkis SJ, Jones RJ: BCR-ABL gene rearrangement and expression of primitive hematopoietic progenitors in chronic myeloid leukemia. Blood 81:2898, 1993
219. Bedi A, Zehnbauer BA, Barber JP, Sharkis SJ, Jones RJ: Inhibition of apoptosis by BCR-ABL in chronic myeloid leukemia. Blood 83:2038, 1994
220. McGahon A, Bissonnette R, Schmitt M, Cotter KM, Green DR, Cotter TG: BCR-ABL maintains resistance of chronic myelogenous leukemia cells to apoptotic cell death [published erratum appears in Blood 83:3835,1994]. Blood 83:1179, 1994
221. Kanei-Ishii C, Nomura T, Ogata K, Sarai A, Yasukawa T, Tashiro S, Takahashi T, Tanaka Y, Ishii S: Structure and function of the proteins encoded by the myb gene family. Curr Top Microbiol Immunol 211:89, 1996
222. Nomura N, Zu YL, Maekawa T, Tabata S, Akiyama T, Ishii S: Isolation and characterization of a novel member of the gene family encoding the cAMP response element-binding protein CRE-BP1. J Biol Chem 268:4259, 1993
223. Biedenkapp H, Borgmeyer U, Sippel AE, Klempnauer KH: Viral myb oncogene encodes a sequence-specific DNA-binding activity. Nature 335:835, 1988
224. Ratajczak MZ, Perrotti D, Melotti P, Powzaniuk M, Calabretta B, Onodera K, Kregenow DA, Machalinski B, Gewirtz AM: Myb and Ets proteins are candidate regulators of c-kit expression in human hematopoietic cells. Blood 91:1934, 1998
225. Siu G, Wurster AL, Lipsick JS, Hedrick SM: Expression of the CD4 gene requires a Myb transcription factor. Mol Cell Biol 12:1592, 1992
226. Melotti P, Ku DH, Calabretta B: Regulation of the expression of the hematopoietic stem cell antigen CD34: Role of c-myb. J Exp Med 179:1023, 1994
227. Gewirtz AM, Calabretta B: A c-myb antisense oligodeoxynucleotide inhibits normal human hematopoiesis in vitro. Science 242:1303, 1988
228. Gewirtz AM, Anfossi G, Venrurelli D, Valpreda S, Sims R, Calabretta B: G1/S transition in normal human T-lymphocytes requires the nuclear protein encoded by c-myb. Science 245:180, 1989
229. Caracciolo D, Venturelli D, Valtieri M, Peschle C, Gewirtz AM, Calabretta B: Stage-related proliferative activity determines c-myb functional requirements during normal human hematopoiesis. J Clin Invest 85:55, 1990
230. Mucenski ML, McLain K, Kier AB, Swerdlow SH, Schreiner CM, Miller TA, Pietryga DW, Scott WJ Jr, Potter SS: A functional c-myb gene is required for normal murine fetal hepatic hematopoiesis. Cell 65:677, 1991
231. Anfossi G, Gewirtz AM, Calabretta B: An oligomer complementary to c-myb-encoded mRNA inhibits proliferation of human myeloid leukemia cell lines. Proc Natl Acad Sci USA 86:3379, 1989
232. Melotti P, Calabretta B: The transcription factors c-myb and GATA-2 act independently in the regulation of normal hematopoiesis. Proc Natl Acad Sci USA 93:5313, 1996
233. Vandenbark GR, Chen Y, Friday E, Pavlik K, Anthony B, deCastro C, Kaufman RE: Complex regulation of human c-kit transcription by promoter repressers, activators, and specific myb elements. Cell Growth Differ 7:1383, 1996
234. Lyman SD, Jacobsen SE: c-kit ligand and Flt3 ligand: stem/ progenitor cell factors with overlapping yet distinct activities. Blood 91:1101, 1998
235. Yu H, Bauer B, Lipke GK, Phillips RL, Van Zant G: Apoptosis and hematopiesis in murine fetal liver. Blood 81:373, 1993
236. Carson WE, Haldar S, Baiocchi RA, Croce CM, Caligiuri MA: The c-kit ligand suppresses apoptosis of human natural killer cells through the upregulation of bcl-2. Proc Natl Acad Sci USA 91:7553, 1994
237. Sawyers CL, Callahan W, Witte ON: Dominant negative MYC blocks transformation by ABL oncogenes. Cell 70:901, 1992
238. Afar DE, Goga A, McLaughlin J, Witte ON, Sawyers CL: Differential complementation of Bcr-Abl point mutants with c-Myc. Science 264:424, 1994
239. Skorski T, Perrotti D, Nieborowska-Skorska M, Gryaznov S, Calabretta B: Antileukemia effect of c-myc N3′ → p5′ phosphoramidate antisense oligonucleotides in vivo. Proc Natl Acad Sci USA 94:3966, 1997
240. Skorski T, Nieborowska-Skorska M, Wlodarski P, Zon G, Iozzo RV, Calabretta B: Antisense oligodeoxynucleotide combination therapy of primary chronic myelogenous leukemia blast crisis in SCID mice. Blood 88:1005, 1996
241. Bonnefoy-Berard N, Munshi A, Yron I, Wu S, Collins TL, Deckert M, Shalom-Barak T, Giampa L, Herben E, Hernandez J, Meller N, Couture C, Altman A: Vav: Function and regulation in hematopoietic cell signaling. Stem Cells 14:250, 1996
242. Katzav S: vav: A molecule for all haemopoiesis? Br J Haematol 81:141, 1992
243. Wulf GM, Adra CN, Um B: Inhibition of hematopoietic development from embryonic stem cells by antisense vav RNA. EMBO J 12:5065, 1993
244. Zhang R, Tsai FY, Orkin SH: Hematopoietic development of vav-/- mouse embryonic stem cells. Proc Natl Acad Sci USA 91:12755, 1994
245. Zhang R, Alt FW, Davidson L, Orkin SH, Swat W: Defective signalling through the T- and B-cell antigen receptors in lymphoid cells lacking the vav proto-oncogene. Nature 374:470, 1995
246. Zmuidzinas A, Fischer KD, Lira SA, Forrester L, Bryant S, Bernstein A, Barbacid M: The vav proto-oncogene is required early in embryogenesis but not for hematopoietic development in vitro. EMBO J 14:1, 1995
247. Prokocimer M, Rotter V: Structure and function of p53 in normal cells and their aberrations in cancer cells: Projection on the hematologic cell lineages. Blood 84:2391, 1994
248. Bayever E, Iversen P: Oligonucleotides in the treatment of leukemia. Hematol Oncol 12:9, 1994
249. Bishop MR, Warkentin PI, Jackson JD, Bayever E, Iversen PL, Whalen VI, Lastovica J, Haines K, Kessinger A: Antisense oligonucleotide OL (1) p53 for in vitro purging of autologous bone marrow in acute myelogenous leukemia. Prog Clin Biol Res 389:183, 1994
250. Bishop MR, Iversen PL, Bayever E, Sharp JG, Greiner TC, Copple BL, Ruddon R, Zon G, Spinolo J, Arneson M, Armitage JO, Kessinger A: Phase I trial of an antisense oligonucleotide OL(1)p53 in hematologic malignancies [see comments]. J Clin Oncol 14:1320, 1996
251. Reed JC, Miyashita T, Takayama S, Wang HG, Sato T, Krajewski S, Aime-Sempe C, Bodrug S, Kitada S, Hanada M: BCL-2 family proteins: Regulators of cell death involved in the pathogenesis of cancer and resistance to therapy. J Cell Biochem 60:23, 1996
252. Cotter FE, Johnson P, Hall P, Pocock C, al Mahdi N, Cowell JK, Morgan G: Antisense oligonucleotides suppress B-cell lymphoma growth in a SCID-hu mouse model. Oncogene 9:3049, 1994
253. Tasset DM, Kubik MF, Steiner W: Oligonucleotide inhibitors of human thrombin that bind distinct epitopes. J Mol Biol 272:688, 1997
254. Henry SP, Novotny W, Leeds J, Auletta C, Kornbrust DJ: Inhibition of coagulation by a phosphorothioate oligonucleotide. Antisense Nucleic Acid Drug Dev 7:503, 1997
255. Eckstein F, Krieg AM, Stein CA, Agrawal S, Beaucage S, Cook PD, Crooke S, Gait MJ, Gewirtz A, Helene C, Miller P, Narayanan R, Nicolin A, Nielsen P, Ohtsuka E, Seliger H, Stec W, Tidd D, Wagner R, Zon J: On the quality control of antisense oligonucleotides [editorial]. Antisense Nucleic Acid Drug Dev 6:149, 1996
256. Matteucci MD, Wagner RW: In pursuit of antisense. Nature 384:20, 1996
257. Wagner RW: The state of the art in antisense research. Nat Med 1:1116, 1995
258. Antisense '97: A roundtable on the state of the industry. Nat Biotechnol 15:519, 1997
259. Gewirtz AM: Perturbing gene expression with oligodeoxynucleo- tides: Research and potential therapeutic applications. Mt Sinai J Med 63:372, 1996
260. Spiller DG, Tidd DM: Nuclear delivery of antisense oligodeoxynucleotides through reversible permeabilization of human leukemia cells with streptolysin O. Antisense Res Dev 5:13, 1995
261. Basu S, Wickstrom E: Temperature and salt dependence of higher order structure formation by antisense c-myc and c-myb phosphorothioate oligodeoxyribonucleotides containing tetraguanylate tracts. Nucleic Acids Res 25:1327, 1997
262. Chavany C, Connell Y, Neckers L: Contribution of sequence and phosphorothioate content to inhibition of cell growth and adhesion caused by c-myc antisense oligomers. Mol Pharmacol 48:738, 1995
263. Mouthon MA, Mitjavila MT, Marquet J, Vainchenker W, Wendung F: Erroneous results of 3H-thymidine incorporation are related to position of thymidine residues in oligodeoxynucleotides. Exp Hematol 22:384, 1994
264. Vaerman JL, Lammineur C, Moureau P, Lewalle P, Deldime F, Blumenfeld M, Maniat P: BCR-ABL antisense oligodeoxyribonucleotides suppress the growth of leukemic and normal hematopoietic cells by a sequence-specific but nonantisense mechanism [see comments]. Blood 86:3891, 1995
265. Stein C, Cohen J: Phosphorothioate oligodeoxynucleotide analogues. Basingstoke, UK, Macmillian, 1989
266. Yaswen P, Stampfer M, Ghosh K, Cohen J: Effects of sequence of thioated oligonucleotides on cultured human mammary epithelial cells. Antisense Res Dev 3:67, 1993
267. Ho PT, Ishiguro K, Wickstrom E, Sartorelli AC: Non-sequence-specific inhibition of transferrin receptor expression in HL-60 leukemia cells by phosphorothioate oligodeoxynucleotides. Antisense Res Dev 1:329, 1991
268. Vickers T, Baker BF, Cook PD, Zounes M, Buckheit RW Jr, Germany J, Ecker DJ: Inhibition of HIV-LTR gene expression by oligonucleotides targeted to the TAR element. Nucleic Acids Res 19:3359, 1991
269. Ghosh MK, Ghosh K, Cohen JS: Translation inhibition by phosphorothioate oligodeoxynucleotides in cell-free systems. Antisense Res Dev 2:111, 1992
270. Teaching editorial: Controls for antisense oligonucleotide experiments [editorial], Antisense Res Dev 1:187, 1991